Publicaciones RedinRen

• Kidney transplantation and enzyme replacement therapy in patients with Fabry disease.

  Cybulla M, Kurschat C, West M, Nicholls K, Torras J, Sunder-Plassmann G et al.. J Nephrol. 2013 Jul-Aug;26(4):645-51.

• Developments in renal pharmacogenomics and applications in chronic kidney disease.

  Padullés A, Rama I, Llaudó I, Lloberas N. Pharmgenomics Pers Med. 2014;7:251-66.

• Belatacept utilization recommendations: an expert position.

  Grinyó JM, Budde K, Citterio F, Charpentier B. Expert Opin Drug Saf. 2013 Jan;12(1):111-22.

• The effect of rabbit antithymocyte globulin on human mesenchymal stem cells.

  Franquesa M, Baan CC, Korevaar SS, Engela AU, Roemeling-van Rhijn M, Weimar W et al.. Transpl Int. 2013 Jun;26(6):651-8.

• Why is organ transplantation clinically important?

  Grinyó JM. Cold Spring Harb Perspect Med. 2013 Jun 1;3(6).

• Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting: lessons learned from first clinical trials.

  Franquesa M, Hoogduijn MJ, Reinders ME, Eggenhofer E, Engela AU, Mensah FK et al.. Transplantation. 2013 Aug 15;96(3):234-8.

• Acute renal failure induced by acute interstitial nephritis secondary to cocaine.

  Gelpi R, Taco O, Gomà M, Torras J, Poveda R, Álvarez T et al.. Nefrologia. 2013;33(4):609-11.

• Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study.

  Rostaing L, Vincenti F, Grinyó J, Rice KM, Bresnahan B, Steinberg S et al.. Am J Transplant. 2013 Nov;13(11):2875-83.

• New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic.

  Ripoll È, Merino A, Grinyó JM, Torras J. Immunotherapy. 2013 Oct;5(10):1089-101.

• Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

  Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y et al.. Am J Transplant. 2013 Nov;13(11):2884-91.

• Measurement of ganciclovir concentration in human plasma by ultra-performance liquid chromatography-tandem mass spectrometry.

  Rigo-Bonnin R, Padullés A, Corral-Comesaña S, Cerezo G, Grinyó JM, Colom H et al.. Clin Chim Acta. 2014 Jan 1;427:58-64.

• Optimal sparse sampling for estimating ganciclovir/valganciclovir AUC in solid organ transplant patients using NONMEN.

  Padullés Caldés A, Colom H, Caldes A, Cerezo G, Torras J, Grinyó JM et al.. Ther Drug Monit. 2014 Jun;36(3):371-7.

• Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients.

  Colom H, Lloberas N, Andreu F, Caldés A, Torras J, Oppenheimer F et al.. Kidney Int. 2014 Jun;85(6):1434-43.

• Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions.

  Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB et al.. Am J Transplant. 2014 Feb;14(2):272-83.

• Differential impact of belatacept and cyclosporine A on central aortic blood pressure and arterial stiffness after renal transplantation.

  Seibert FS, Steltzer J, Melilli E, Grannas G, Pagonas N, Bauer F et al.. Clin Transplant. 2014 Sep;28(9):1004-9.

• Induction of suppressive allogeneic regulatory T-cells via rabbit-ATG during homeostatic proliferation in rat kidney transplantation.

  Valdez-Ortiz R, Bestard O, Llaudó I, Franquesa M, Cerezo G, Torras J et al.. Transpl Int. 2014 Sep 10;.

• Novel Once-Daily Extended-Release Tacrolimus (LCPT) Versus Twice-Daily Tacrolimus in De Novo Kidney Transplants: One-Year Results of Phase III, Double-Blind, Randomized Trial.

  Budde K, Bunnapradist S, Grinyo JM, Ciechanowski K, Denny JE, Silva HT et al.. Am J Transplant. 2014 Oct 2;.

• Preformed Frequencies of Cytomegalovirus (CMV)-Specific Memory T and B Cells Identify Protected CMV-Sensitized Individuals Among Seronegative Kidney Transplant Recipients.

  Lúcia M, Crespo E, Melilli E, Cruzado JM, Luque S, Llaudó I et al.. Clin Infect Dis. 2014 Jul 21;.

• Extensively Drug-Resistant Pseudomonas aeruginosa Bacteremia in Solid Organ Transplant Recipients.

  Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, González-Costello J et al.. Transplantation. 2014 Aug 12;.

• Development of a population PK model of Tacrolimus for adaptive dosage control in stable kidney transplant patients.

  Andreu F, Colom H, Grinyó JM, Torras J, Cruzado JM, Lloberas N. Ther Drug Monit. 2014 Sep 24;.

• [Early detection, prevention and management of renal failure in liver transplantation].

  Castells L, Baliellas C, Bilbao I, Cantarell C, Cruzado JM, Esforzado N. Gastroenterol Hepatol. 2014 Oct;37(8):480-91.

• Low serum mannose-binding lectin levels are associated with inflammation and apoptosis in early surveillance allograft biopsies.

  Ibernon M, Moreso F, O'Valle F, Grinyo JM, Moral RG, Seron D. Transpl Immunol. 2014 Sep;31(3):152-6.

• Early-onset anemia after kidney transplantation is an independent factor for graft loss: a multicenter, observational cohort study.

  Pascual J, Jiménez C, Franco A, Gil M, Obrador-Mulet AR, Gentil MA. Transplantation. 2013 Oct 27;96(8):717-25.

• Mechanisms and risk factors for the development of the proteinuria after kidney transplantation.

  Melilli E, Cruzado JM, Bestard O, Hernández D. Transplant Rev (Orlando). 2012 Jan;26(1):14-9.

• IgA nephropathy recurs early in the graft when assessed by protocol biopsy.

  Ortiz F, Gelpi R, Koskinen P, Manonelles A, Räisänen-Sokolowski A, Carrera M. Nephrol Dial Transplant. 2012 Jun;27(6):2553-8.

• Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation.

  Cruzado JM, Bestard O, Grinyó JM. Contrib Nephrol. 2012;176:108-16.

• Fever in a kidney transplant recipient: no facts and many interactions.

  López-Medrano F, Carratalà J, Cruzado JM, Gutiérrez MJ, Aguado JM. Rev Clin Esp. 2012 Apr;212(4):193-7.

• Immunosuppression in the era of biological agents.

  Grinyó JM, Cruzado JM, Bestard O, Vidal Castiñeira JR, Torras J. Adv Exp Med Biol. 2012;741:60-72.

• Hepatocyte growth factor gene therapy enhances infiltration of macrophages and may induce kidney repair in db/db mice as a model of diabetes.

  Flaquer M, Franquesa M, Vidal A, Bolaños N, Torras J, Lloberas N. Diabetologia. 2012 Jul;55(7):2059-68.

• Mesenchymal stem cell therapy prevents interstitial fibrosis and tubular atrophy in a rat kidney allograft model.

  Franquesa M, Herrero E, Torras J, Ripoll E, Flaquer M, Gomà M. Stem Cells Dev. 2012 Nov 20;21(17):3125-35.

• Successful outcome of ganciclovir-resistant cytomegalovirus infection in organ transplant recipients after conversion to mTOR inhibitors.

  Sabé N, González-Costello J, Rama I, Niubó J, Bodro M, Roca J. Transpl Int. 2012 Jul;25(7):e78-82.

• Long-term results of biopsy-guided selection and allocation of kidneys from older donors in older recipients.

  Fernández-Lorente L, Riera L, Bestard O, Carrera M, Gomà M, Porta N. Am J Transplant. 2012 Oct;12(10):2781-8.

• Sirolimus and secondary skin-cancer prevention in kidney transplantation.

  Euvrard S, Morelon E, Rostaing L, Goffin E, Brocard A, Tromme I. N Engl J Med. 2012 Jul 26;367(4):329-39.

• Geriatric assessment and chronic kidney disease in the oldest old: the Octabaix study.

  Formiga F, Ferrer A, Cruzado JM, Padros G, Fanlo M, Roson B. Eur J Intern Med. 2012 Sep;23(6):534-8.

• Impact of small molecules immunosuppressants on P-glycoprotein activity and T-cell function.

  Llaudó I, Cassis L, Torras J, Bestard O, Franquesa Ml, Cruzado JM. J Pharm Pharm Sci. 2012;15(3):407-19.

• Harmful effects of viral replication in seropositive hepatitis C virus renal transplant recipients.

  Gentil Govantes MA, Esforzado N, Cruzado JM, González-Roncero FM, Balaña M, Saval N. Transplantation. 2012 Dec 15;94(11):1131-7.

• Clinical features and outcomes of tuberculosis in solid organ transplant recipients.

  Bodro M, Sabé N, Santín M, Cruzado JM, Lladó L, González-Costello J. Transplant Proc. 2012 Nov;44(9):2686-9.

• Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study.

  Llaudó I, Colom H, Giménez-Bonafé P, Torras J, Caldés A, Sarrias M. Transpl Int. 2013 Feb;26(2):177-86.

• Kidney regeneration and repair after transplantation.

  Franquesa M, Flaquer M, Cruzado JM, Grinyó JM. Curr Opin Organ Transplant. 2013 Apr;18(2):191-6.

• Kidney Transplantation Group of the Spanish Society of Nephrology.

  Pascual J, Cruzado JM, Alonso A, Diekman F, Gallego RJ, Gutiérrez-Dalmau A. Nefrologia. 2013;33(2):160-3.

• Executive summary. Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).

  López-Medrano F, Cordero E, Gavaldá J, Cruzado JM, Marcos MÁ, Pérez-Romero P. Enferm Infecc Microbiol Clin. 2013 Oct;31(8):528-34.

• Management of influenza infection in solid-organ transplant recipients: consensus statement of the Group for the Study of Infection in Transplant Recipients (GESITRA) of the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC) and the Spanish Network for Research in Infectious Diseases (REIPI).

  López-Medrano F, Cordero E, Gavaldá J, Cruzado JM, Marcos MÁ, Pérez-Romero P. Enferm Infecc Microbiol Clin. 2013 Oct;31(8):526.e1-526.e20.

• Dendritic cells phenotype fitting under hypoxia or lipopolysaccharide; adenosine 5'-triphosphate-binding cassette transporters far beyond an efflux pump.

  Lloberas N, Rama I, Llaudó I, Torras J, Cerezo G, Cassis L. Clin Exp Immunol. 2013 Jun;172(3):444-54.

• Pretransplant immediately early-1-specific T cell responses provide protection for CMV infection after kidney transplantation.

  Bestard O, Lucia M, Crespo E, Van Liempt B, Palacio D, Melilli E. Am J Transplant. 2013 Jul;13(7):1793-805.

• Cross-validation of IFN-γ Elispot assay for measuring alloreactive memory/effector T cell responses in renal transplant recipients.

  Bestard O, Crespo E, Stein M, Lúcia M, Roelen DL, de Vaal YJ. Am J Transplant. 2013 Jul;13(7):1880-90.

• Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation.

  Bestard O, Cruzado JM, Lucia M, Crespo E, Casis L, Sawitzki B. Kidney Int. 2013 Dec;84(6):1226-36.

• CD40 gene silencing reduces the progression of experimental lupus nephritis modulating local milieu and systemic mechanisms.

  Ripoll È, Merino A, Goma M, Aran JM, Bolaños N, de Ramon L. PLoS One. 2013;8(6):e65068.

• Risk factors and outcomes of bacteremia caused by drug-resistant ESKAPE pathogens in solid-organ transplant recipients.

  Bodro M, Sabé N, Tubau F, Lladó L, Baliellas C, Roca J. Transplantation. 2013 Nov 15;96(9):843-9.

• Successful treatment of chronic HCV infection should not preclude kidney donation to an HCV negative recipient.

  Cruzado JM, Gil-Vernet S, Castellote J, Bestard O, Melilli E, Grinyó JM. Am J Transplant. 2013 Oct;13(10):2773-4.

• Correction: CD40 Gene Silencing Reduces the Progression of Experimental Lupus Nephritis Modulating Local Milieu and Systemic Mechanisms.

  Ripoll E, Merino A, Goma M, Aran JM, Bolaños N, de Ramon L. PLoS One. 2013;8(8).

• Sterile leukocyturia is associated with interstitial fibrosis and tubular atrophy in kidney allograft protocol biopsies.

  Coelho S, Ortíz F, Gelpi R, Koskinen P, Porta N, Bestard O. Am J Transplant. 2014 Apr;14(4):908-15.

• Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigm.

  Lúcia M, Crespo E, Cruzado JM, Grinyó JM, Bestard O. Transpl Int. 2014 Mar 15;.